References of "Rabenda, Véronique"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials.
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Rabenda, Véronique ULg et al

in The Journal of clinical endocrinology and metabolism (in press)

Context There is growing evidence that vitamin D plays a role on several tissues including skeletal muscle. Objective To summarize with a meta-analyse the effects of vitamin D supplementation on muscle ... [more ▼]

Context There is growing evidence that vitamin D plays a role on several tissues including skeletal muscle. Objective To summarize with a meta-analyse the effects of vitamin D supplementation on muscle function. Data sources A systematic research of randomized controlled trials, performed between 1966 and January 2014 has been conducted on Medline, Cochrane Database of Systematics Reviews, Cochrane Central Register of Controlled and completed by a manual review of the literature and congressional abstracts. Study selection All forms and doses of vitamin D supplementation, with or without calcium supplementation, compared with placebo or control were included. Out of the 225 potentially relevant articles, 30 randomized controlled trials involving 5615 individuals (mean age: 61.1 years) met the inclusion criteria. Data extraction Data were extracted by two independent reviewers. Data synthesis Results revealed a small but significant positive effect of vitamin D supplementation on global muscle strength with a standardized mean difference (SMD) of 0.17 (p=0.02). No significant effect was found on muscle mass (SMD 0.058; p=0.52) or muscle power (SMD 0.057; p=0.657). Results on muscle strength were significantly more important with people who presented a 25-hydroxyvitamin D level <30 nmol/L. Supplementation seems also more effective on people aged 65 years or older compared to younger subjects (SMD 0.25; 95% CI 0.01 to 0.48 versus SMD 0.03; 95% CI -0.08 to 0.14). Conclusions Vitamin D supplementation has a small positive impact on muscle strength but additional studies are needed to define optimal treatment modalities, including dose, mode of administration and duration. [less ▲]

Detailed reference viewed: 16 (6 ULg)
Full Text
Peer Reviewed
See detailDabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Douxfils, Jonathan; Buckinx, Fanny ULg; Mullier, Francois et al

in Journal of the American Heart Association (in press)

BACKGROUND: Signals of an increased risk of myocardial infarction (MI) have been identified with dabigatran etexilate in randomized controlled trials (RCTs). METHODS AND RESULES: We conducted searches of ... [more ▼]

BACKGROUND: Signals of an increased risk of myocardial infarction (MI) have been identified with dabigatran etexilate in randomized controlled trials (RCTs). METHODS AND RESULES: We conducted searches of the published literature and a clinical trials registry maintained by the drug manufacturer. Criteria for inclusion in our meta-analysis included all RCTs and the availability of outcome data for MI, other cardiovascular events, major bleeding, and all-cause mortality. Among the 501 unique references identified, 14 RCTs fulfilled the inclusion criteria. Stratification analyses by comparators and doses of dabigatran etexilate were conducted. Peto odds ratio (ORPETO) values using the fixed-effect model (FEM) for MI, other cardiovascular events, major bleeding, and all-cause mortality were 1.34 (95% CI 1.08 to 1.65, P=0.007), 0.93 (95%CI 0.83 to 1.06, P=0.270), 0.88 (95% CI 0.79 to 0.99, P=0.029), and 0.89 (95% CI 0.80 to 1.00, P=0.041). When compared with warfarin, ORPETO values using FEM were 1.41 (95% CI 1.11 to 1.80, P=0.005), 0.94 (95%CI 0.83 to 1.06, P=0.293), 0.85 (95% CI 0.76 to 0.96, P=0.007), and 0.90 (95% CI 0.81 to 1.01, P=0.061), respectively. In RCTs using the 150-mg BID dosage, the ORPETO values using FEM were 1.45 (95% CI 1.11 to 1.91, P=0.007), 0.95 (95% CI 0.82 to 1.09, P=0.423), 0.92 (95% CI 0.81 to 1.05, P=0.228), and 0.88 (95% CI 0.78 to 1.00, P=0.045), respectively. The results of the 110-mg BID dosage were mainly driven by the RE-LY trial. CONCLUSIONS: This meta-analysis provides evidence that dabigatran etexilate is associated with a significantly increased risk of MI. This increased risk should be considered taking into account the overall benefit in terms of major bleeding and all-cause mortality. [less ▲]

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailLes effets d'une supplémentation en vitamine D sur la force musculaire : une méta-analyse d'essais randomisés contrôlés
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Rabenda, Véronique ULg et al

in Cahiers de l'Année Gérontologique (Les) (2013, September), 5(1-2), 38

Detailed reference viewed: 36 (11 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Rheumatology International (2013), 33(4), 979-83

The FRAX tool that calculates the 10-year probability of having a fracture has recently been validated for Belgium. Little is known about the perception and knowledge that GPs have about this tool in ... [more ▼]

The FRAX tool that calculates the 10-year probability of having a fracture has recently been validated for Belgium. Little is known about the perception and knowledge that GPs have about this tool in their daily practice. A survey has been conducted as part of a screening campaign for various diseases. The primary objective of the present study was to assess the perception and the knowledge of the FRAX tool by GPs. The secondary objective was to assess the impact of an information brochure about the FRAX tool on these outcomes. The survey was sent to a sample of 700 GPs after only half of them had received the information brochure. The survey results show that, out of the 193 doctors who responded to the survey, one-third know the FRAX tool but less than 20 % use it in their daily clinical practice. Among those who use it, the FRAX tool is largely seen as a complementary but not as an essential tool in the diagnosis or in the management of osteoporosis. It appears that the brochure could improve the knowledge of the FRAX tool but it would not be more efficient on its use in daily practice than the other sources of information. At present, the use of the FRAX tool in Belgium is limited but an information brochure could have a positive impact on the knowledge of the FRAX tool. [less ▲]

Detailed reference viewed: 21 (10 ULg)
Full Text
Peer Reviewed
See detailChanges in the structure and the symptoms of the osteoarthritis knee and prediction of future knee replacement over an 8-year follow-up period
Bruyère, Olivier ULg; Cooper, Cyrus; Pavelka, Karel et al

in Osteoporosis International (2013, April), 24(Suppl.1), 209

Detailed reference viewed: 35 (17 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Rabenda, Véronique ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 198

Detailed reference viewed: 30 (5 ULg)
Full Text
Peer Reviewed
See detailChanges in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years.
Bruyère, Olivier ULg; Cooper, Cyrus; Pavelka, Karel et al

in Calcified Tissue International (2013), 93

The objective of this study was to assess the association between changes in joint space width (JSW, i.e., structure) or Western Ontario and McMaster Universities (WOMAC) score (i.e., symptoms) over 3 ... [more ▼]

The objective of this study was to assess the association between changes in joint space width (JSW, i.e., structure) or Western Ontario and McMaster Universities (WOMAC) score (i.e., symptoms) over 3 years in patients with knee osteoarthritis and the occurrence of knee replacement over 8 years. We followed 133 subjects with primary knee osteoarthritis prospectively for a mean of 8 years. JSW (standard radiography) and symptoms (total WOMAC score) were assessed every year for 3 years. The rate of knee replacement was recorded for the following 5 years. Logistic regressions were performed according to the intention-to-treat principle. After 8 years' follow-up, ten patients (7.5 %) had undergone a knee replacement. The changes in JSW or WOMAC score over 3 years were significantly associated with the occurrence of knee replacement during the following 5 years (p = 0.02 and p = 0.03, respectively). Each 0.1-mm narrowing of JSW over 3 years was associated with a 14 % (95 % CI 3-25 %) increased risk for knee replacement. For every 10 % increase in WOMAC score, the risk for joint replacement was increased by 16 % (95 % CI 1-33 %). When JSW and WOMAC score were included in the same statistical model, they were still significantly associated with risk for knee replacement (p = 0.02 and p = 0.03, respectively), but JSW change was the only variable that remained significant after adjusting for all potential confounders. Our results suggest that changes in symptoms and, more particularly, in structure over 3 years in patients with osteoarthritis reflect a clinically relevant progression of the disease. [less ▲]

Detailed reference viewed: 27 (12 ULg)
Full Text
Peer Reviewed
See detailRelationship between use of antidepressants and risk of fractures: a meta-analysis
Rabenda, Véronique ULg; Nicolet, Delphine ULg; Beaudart, Charlotte ULg et al

in Osteoporosis International (2013), 24

Summary It has been shown that antidepressants would have a direct action on bone metabolism and would be associated with increased fracture risk. Results from this large meta-analysis show that both ... [more ▼]

Summary It has been shown that antidepressants would have a direct action on bone metabolism and would be associated with increased fracture risk. Results from this large meta-analysis show that both SSRIs and TCAs are associated with a moderate and clinically significant increase in the risk of fractures of all types. Introduction This study seeks to investigate the relationship between use of antidepressants and the risk of fracture. Methods An exhaustive systematic research of case–control and cohort studies published or performed between 1966 and April 2011 that reported risk estimates of fracture associated with use of antidepressants was performed using MEDLINE, PsycINFO, and the Cochrane Systematic Review Database, manual review of the literature, and congressional abstracts. Inclusion, quality scoring, and data abstraction were performed systematically by three independent reviewers. Results A total of 34 studies (n01,217,464 individuals) were identified. Compared with non-users, the random effects pooled RR of fractures of all types, among antidepressant users, were 1.39 (95%CI 1.32–1.47). Use of antidepressants were associated with a 42 %, 47 %, and 38 % risk increase in non-vertebral, hip, and spine fractures, respectively ([For non-vertebral fractures: RR01.42, 95%CI 1.34–1.51]; [For hip fractures: RR01.47, 95%CI 1.36–1.58]; [For spine fractures: RR01.38, 95%CI 1.19–1.61]). Studies examining SSRI use showed systematically a higher increase in the risk of fractures of all types, non-vertebral, and hip fractures than studies evaluating TCA use. Conclusions Results from this large meta-analysis show that both SSRIs and TCAs are associated with a moderate and clinically significant increase in the risk of fractures of all types. [less ▲]

Detailed reference viewed: 46 (23 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge and use by general practitioners of Belgium of the FRAX tool
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 716

Detailed reference viewed: 18 (4 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge and use by general practitioners of Belgium of the FRAX tool
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 363-364

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailEffect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study
Bruyère, Olivier ULg; Zegels, Brigitte ULg; LEONORI, Lorenzo ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 362-363

Detailed reference viewed: 41 (8 ULg)
Full Text
Peer Reviewed
See detailRisk of nonvertebral fractures among elderly postmenopausal women using antidepressants
Rabenda, Véronique ULg; Bruyère, Olivier ULg; REGINSTER, Jean-Yves ULg

in Bone (2012), 51(4), 674-679

Objective: To examine the association between antidepressants, including TCAs, SSRIs, and miscellaneous antidepressants and the risk of nonvertebral fractures among women with osteoporosis. Materials and ... [more ▼]

Objective: To examine the association between antidepressants, including TCAs, SSRIs, and miscellaneous antidepressants and the risk of nonvertebral fractures among women with osteoporosis. Materials and methods: This study was a post-hoc analysis of pooled data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]). A nested case-control study was performed in the placebo treated population. Adjusted logistic regression models were used to estimate the risk of nonvertebral fracture associated with the use of antidepressants. Results: After 3. years of follow-up, 391 nonvertebral fractures cases were identified and matched to 1955 controls. Compared with non-users of antidepressants, antidepressants use was associated with an increased risk of nonvertebral fractures (adjusted OR=1.64; 95%CI, 1.03-2.62]). Particularly, there was a 2-fold risk increase (95%CI, 1.07-3.79) of nonvertebral fracture for current users of SSRIs and a 2.1-fold risk increase for subjects who were current users of TCAs (95%CI, 1.02-4.30). Among patients categorized as recent or past users, none of the classes of antidepressants were statistically associated with increased risk of nonvertebral fracture. Conclusions: Our findings confirm that both SSRIs and TCAs increase the risk of nonvertebral fracture in current users. © 2012 Elsevier Inc. [less ▲]

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULg et al

in BONE (2012), 51

Detailed reference viewed: 8 (1 ULg)